日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sequential Portal Vein-Hepatic Vein Embolization: Progress Yet Unaccounted Pitfalls

门静脉-肝静脉序贯栓塞术:进展与未知风险

Shahid, Syeda Rabiah; Anjum, Ahmad Furqan

Advancing hypoparathyroidism treatment: FDA approval of Palopegteriparatide as a promising orphan drug

推进甲状旁腺功能减退症的治疗:FDA批准帕洛佩格特里帕肽作为一种有前景的孤儿药

Shahid, Syeda Rabiah; Shahid, Kamran; Ehsan, Sikandar; Khalid, Maliha; Waafira, Aminath

Rapidly enlarging dermatofibrosarcoma protuberans: a case report of atypical presentation with diagnostic complexities and reconstructive challenges

快速增大的隆突性皮肤纤维肉瘤:一例表现不典型、诊断复杂且重建困难的病例报告

Shahid, Syeda Rabiah; Khalid, Maliha; Waafira, Aminath

FDA approval of prademagene zamikeracel (Zevaskyn): advancing gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) patients

FDA 批准 prademagene zamikeracel (Zevaskyn):推进隐性营养不良性大疱性表皮松解症 (RDEB) 患者的基因治疗

Shahid, Syeda Rabiah; Shahid, Kamran; Khalid, Maliha; Waafira, Aminath

Cardiac organoids: tailoring presurgical drug testing for heart failure patients

心脏类器官:为心力衰竭患者量身定制术前药物测试

Shahid, Syeda Rabiah; Talha, Muhammad; Siddiqui, Araj Naveed; Yokolo, Hermann

Redefining uUTI therapy: Orlynvah as a promising oral alternative (sulopenem etzadroxil and probenecid)

重新定义尿路感染治疗:Orlynvah 是一种有前景的口服替代疗法(磺洛培南艾司羟甲酯和丙磺舒)

Shahid, Kamran; Shahid, Syeda Rabiah; Khalid, Maliha; Waafira, Aminath

Breaking chains: IMAAVY redefines generalized myasthenia gravis treatment

打破恶性循环:IMAAVY重新定义全身型重症肌无力治疗

Shahid, Kamran; Shahid, Syeda Rabiah; Khalid, Maliha; Waafira, Aminath

From case series to clinical practice: Evaluating thoracic duct decompression for Fontan-associated protein-losing enteropathy

从病例系列到临床实践:评估胸导管减压术治疗Fontan相关蛋白丢失性肠病

Shahid, Syeda Rabiah; Hamza, Muhammad; Iqbal, Javed